# Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

> **NCT03233724** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Cancer
- Non-Small Cell Lung Cancer
- Carcinoma, Esophageal
- Malignant Pleural Mesotheliomas

## Interventions

- **DRUG:** Decitabine (DAC)
- **DRUG:** Tetrahydrouridine (THU)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03233724
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-11
- **Primary completion:** 2021-10-06
- **Final completion:** 2021-10-26
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study terminated due to drug supply issues.
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03233724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03233724, "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03233724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*